{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:36:34Z","timestamp":1776400594631,"version":"3.51.2"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pharmalink International Ltd. Central, Hong Kong","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Pulmonary hypertension (PH) in dogs, characterized by abnormally high blood pressure in the pulmonary arteries, presents a management challenge, and adjunctive therapies for the standard treatment of sildenafil are needed. This study aimed to determine whether the nutraceutical <jats:italic>Perna canaliculus<\/jats:italic> oil (PCSO-524), a marine lipid extract with anti-inflammatory properties, provides additional clinical benefits to dogs with PH. In a prospective, randomized, placebo-controlled trial, seventeen client-owned dogs diagnosed with PH were assigned to receive either PCSO-524 or a placebo as an add-on to their sildenafil-based therapy for 70 days. Key outcomes were evaluated using owner-assessed clinical scores for exercise tolerance and coughing, alongside echocardiographic measurements. The PCSO-524 group demonstrated a statistically significant improvement in exercise tolerance scores by day 70 (P\u2009=\u20090.009). This group also showed a greater reduction in coughing scores compared to the placebo group between day 35 and day 70 (P\u2009=\u20090.03). While the tricuspid regurgitation pressure gradient (TRPG), an estimate of pulmonary pressure, decreased significantly over time in all dogs (P\u2009=\u20090.001), no significant difference was found between the groups for this specific measure. These results indicate that PCSO-524 can serve as a beneficial adjunctive therapy for improving important clinical signs, such as exercise tolerance and coughing, in dogs with PH. This suggests it may be a valuable addition to standard management for enhancing quality of life.<\/jats:p>","DOI":"10.1371\/journal.pone.0333526","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:33:19Z","timestamp":1759167199000},"page":"e0333526","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical improvement in canine pulmonary hypertension with Perna canaliculus oil (PCSO-524) add-on therapy: Effects on exercise tolerance and cough"],"prefix":"10.1371","volume":"20","author":[{"given":"Nattapon","family":"Riengvirodkij","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mookmanee","family":"Taechikantaphat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pichayut","family":"Ampapol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theethach","family":"Kovorakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sapon","family":"Intaranat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8245-9506","authenticated-orcid":true,"given":"Walasinee","family":"Sakcamduang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"5","key":"pone.0333526.ref001","first-page":"440","article-title":"Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992-1996","volume":"13","author":"L Johnson","year":"1999","journal-title":"J Vet Intern Med"},{"issue":"6","key":"pone.0333526.ref002","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1939-1676.2007.tb01947.x","article-title":"Sildenafil citrate therapy in 22 dogs with pulmonary hypertension","volume":"21","author":"HB Kellum","year":"2007","journal-title":"J Vet Intern Med"},{"issue":"2","key":"pone.0333526.ref003","first-page":"99","article-title":"Pulmonary hypertension and cardiovascular sequelae in 54 dogs","volume":"2","author":"RL Pyle","year":"2004","journal-title":"Intern J Appl Res Vet Med"},{"issue":"6","key":"pone.0333526.ref004","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1939-1676.2009.0390.x","article-title":"Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs","volume":"23","author":"KJ Atkinson","year":"2009","journal-title":"J Vet Intern Med"},{"issue":"2","key":"pone.0333526.ref005","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/jvim.15725","article-title":"ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs","volume":"34","author":"C Reinero","year":"2020","journal-title":"J Vet Intern Med"},{"issue":"1","key":"pone.0333526.ref006","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jvc.2012.01.001","article-title":"Pulmonary hypertension in canine degenerative mitral valve disease","volume":"14","author":"HB Kellihan","year":"2012","journal-title":"J Vet Cardiol"},{"issue":"3","key":"pone.0333526.ref007","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/jvim.15488","article-title":"ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs","volume":"33","author":"BW Keene","year":"2019","journal-title":"J Vet Intern Med"},{"issue":"7","key":"pone.0333526.ref008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254887","article-title":"Protective effects of omega-3 fatty acids in dogs with myxomatous mitral valve disease stages B2 and C","volume":"16","author":"PR Nasciutti","year":"2021","journal-title":"PLoS One"},{"key":"pone.0333526.ref009","doi-asserted-by":"crossref","unstructured":"Mickleborough TD, Sinex JA, Platt D, Chapman RF, Hirt MJJotISoSN. The effects PCSO-524\u00ae, a patented marine oil lipid and omega-3 PUFA blend derived from the New Zealand green lipped mussel (Perna canaliculus), on indirect markers of muscle damage and inflammation after muscle damaging exercise in untrained men: a randomized, placebo controlled trial. 2015;12(1):10.","DOI":"10.1186\/s12970-015-0073-z"},{"issue":"4","key":"pone.0333526.ref010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11745-006-1394-0","article-title":"Gas chromatography-chemical ionization-mass spectrometric fatty acid analysis of a commercial supercritical carbon dioxide lipid extract from New Zealand green-lipped mussel (Perna canaliculus)","volume":"40","author":"CJ Wolyniak","year":"2005","journal-title":"Lipids"},{"issue":"6","key":"pone.0333526.ref011","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/j.1939-1676.2009.0392.x","article-title":"Guidelines for the diagnosis and treatment of canine chronic valvular heart disease","volume":"23","author":"C Atkins","year":"2009","journal-title":"J Vet Intern Med"},{"issue":"3","key":"pone.0333526.ref012","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cbpb.2006.11.001","article-title":"Anti-cyclooxygenase effects of lipid extracts from the New Zealand green-lipped mussel, Perna canaliculus","volume":"146","author":"S McPhee","year":"2007","journal-title":"Comp Biochem Physiol B Biochem Mol Biol"},{"key":"pone.0333526.ref013","article-title":"Treatment of knee osteoarthritis with Lyprinol\u00ae, lipid extract of the green-lipped mussel - a double-blind placebo-controlled study","author":"C Lau","year":"2004","journal-title":"Progress Nutrition"},{"issue":"4","key":"pone.0333526.ref014","first-page":"244","article-title":"Measurement of pain relief resulting from the administration of Perna canaliculus lipid complex PCSO-524\u2122 as compared to fish oil for treating patients who suffer from osteoarthritis of knee and\/or hip joints","volume":"49","author":"J Szechi\u0144ski","year":"2011","journal-title":"Reumatologia\/Rheumatology"},{"issue":"1","key":"pone.0333526.ref015","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12917-019-2110-7","article-title":"The effectiveness of marine based fatty acid compound (PCSO-524) and firocoxib in the treatment of canine osteoarthritis","volume":"15","author":"M Vijarnsorn","year":"2019","journal-title":"BMC Vet Res"},{"issue":"6","key":"pone.0333526.ref016","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3390\/md11061920","article-title":"Perna canaliculus lipid complex PCSO-524\u2122 demonstrated pain relief for osteoarthritis patients benchmarked against fish oil, a randomized trial, without placebo control","volume":"11","author":"M Zawadzki","year":"2013","journal-title":"Mar Drugs"},{"issue":"6","key":"pone.0333526.ref017","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.5455\/OVJ.2024.v14.i6.10","article-title":"How accurate are NT-proBNP, ANP, and cTnI levels in diagnosing dogs with myxomatous mitral valve disease?","volume":"14","author":"K Chanmongkolpanit","year":"2024","journal-title":"Open Vet J"},{"issue":"9","key":"pone.0333526.ref018","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.5455\/OVJ.2024.v14.i9.11","article-title":"Alteration of clinical parameters before mortality and prognostic outcomes of pulmonary hypertension in dogs with myxomatous mitral valve disease","volume":"14","author":"P Channgam","year":"2024","journal-title":"Open Vet J"},{"issue":"2","key":"pone.0333526.ref019","first-page":"9","article-title":"Assessment of two new commercial rapid tests for canine N-terminal Pro-B-type natriuretic peptide to distinguish the severity of mitral valve disease in dogs","volume":"14","author":"N Riengvirodkij","year":"2021","journal-title":"J Appl Animal Sci"},{"issue":"6","key":"pone.0333526.ref020","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1740-8261.2002.tb01051.x","article-title":"Left atrial to aortic root indices using two-dimensional and M-mode echocardiography in cavalier King Charles spaniels with and without left atrial enlargement","volume":"43","author":"K Hansson","year":"2002","journal-title":"Vet Radiol Ultrasound"},{"issue":"3","key":"pone.0333526.ref021","first-page":"311","article-title":"Allometric scaling of M-mode cardiac measurements in normal adult dogs","volume":"18","author":"CC Cornell","year":"2004","journal-title":"J Vet Intern Med"},{"issue":"8","key":"pone.0333526.ref022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255611","article-title":"Peptide barcodes in dogs affected by mitral valve disease with and without pulmonary hypertension using MALDI-TOF MS and LC-MS\/MS","volume":"16","author":"N Riengvirodkij","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"pone.0333526.ref023","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/jvim.12311","article-title":"Longitudinal electrocardiographic evaluation of dogs with degenerative mitral valve disease","volume":"28","author":"J L\u00f3pez-Alvarez","year":"2014","journal-title":"J Vet Intern Med"},{"issue":"1","key":"pone.0333526.ref024","doi-asserted-by":"crossref","first-page":"59","DOI":"10.56808\/2985-1130.2367","article-title":"Effects of behavior responses on the vasovagal tonus index in healthy dogs","volume":"49","author":"W Moonarmart","year":"2012","journal-title":"Thai J Veterinary Med"},{"key":"pone.0333526.ref025","article-title":"Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: The QUEST study","author":"J H\u00e4ggstr\u00f6m","year":"2008","journal-title":"J Vet Intern Med"},{"issue":"3","key":"pone.0333526.ref026","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10787-997-0002-0","article-title":"Anti-inflammatory activity of a lipid fraction (lyprinol) from the NZ green-lipped mussel","volume":"5","author":"MW Whitehouse","year":"1997","journal-title":"Inflammopharmacology"},{"issue":"4","key":"pone.0333526.ref027","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1939-1676.2010.0517.x","article-title":"Clinical efficacy of sildenafil in treatment of pulmonary arterial hypertension in dogs","volume":"24","author":"AJ Brown","year":"2010","journal-title":"J Vet Intern Med"},{"issue":"2","key":"pone.0333526.ref028","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/jvim.12564","article-title":"Prevalence and prognostic importance of pulmonary hypertension in dogs with myxomatous mitral valve disease","volume":"29","author":"M Borgarelli","year":"2015","journal-title":"J Vet Intern Med"},{"issue":"1","key":"pone.0333526.ref029","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1292\/jvms.14-0050","article-title":"Predictive model for the detection of pulmonary hypertension in dogs with myxomatous mitral valve disease","volume":"77","author":"S Mikawa","year":"2015","journal-title":"J Vet Med Sci"},{"issue":"11","key":"pone.0333526.ref030","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.2460\/javma.229.11.1772","article-title":"Doppler echocardiography-derived evidence of pulmonary arterial hypertension in dogs with degenerative mitral valve disease: 86 cases (2001-2005)","volume":"229","author":"FJ Serres","year":"2006","journal-title":"J Am Vet Med Assoc"},{"key":"pone.0333526.ref031","article-title":"Pulmonary hypertension due to left heart diseases","volume":"62","author":"J-L Vachi\u00e9ry","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"pone.0333526.ref032","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/vcp.13101","article-title":"Analytical validation of a novel point-of-care immunoassay for canine N-terminal pro-brain natriuretic peptide analysis","volume":"51","author":"KE Harr","year":"2022","journal-title":"Vet Clin Pathol"},{"issue":"1","key":"pone.0333526.ref033","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.amjcard.2014.10.008","article-title":"Usefulness of neutrophil-to-lymphocyte ratio in risk stratification of patients with advanced heart failure","volume":"115","author":"VA Benites-Zapata","year":"2015","journal-title":"Am J Cardiol"},{"issue":"3","key":"pone.0333526.ref034","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3390\/ani11030778","article-title":"Red cell distribution width has a negative prognostic role in dogs with myxomatous mitral valve disease","volume":"11","author":"C Guglielmini","year":"2021","journal-title":"Animals (Basel)"},{"issue":"8","key":"pone.0333526.ref035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104861","article-title":"Prognostic value of red blood cell distribution width for patients with heart failure: a systematic review and meta-analysis of cohort studies","volume":"9","author":"YL Huang","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"pone.0333526.ref036","article-title":"Severity of myxomatous mitral valve disease in dogs may be predicted using neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratio","volume":"84","author":"D Ku","year":"2023","journal-title":"Am J Vet Res"},{"key":"pone.0333526.ref037","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ijcard.2014.11.042","article-title":"Prognostic value of red blood cell distribution width in heart failure patients: a meta-analysis","volume":"179","author":"Q Shao","year":"2015","journal-title":"Int J Cardiol"},{"issue":"3","key":"pone.0333526.ref038","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.amjcard.2010.09.039","article-title":"Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure","volume":"107","author":"S Uthamalingam","year":"2011","journal-title":"Am J Cardiol"},{"issue":"5","key":"pone.0333526.ref039","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1939-1676.2008.0150.x","article-title":"Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study","volume":"22","author":"J H\u00e4ggstr\u00f6m","year":"2008","journal-title":"J Vet Intern Med"},{"issue":"3","key":"pone.0333526.ref040","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2460\/ajvr.2004.65.311","article-title":"Evaluation of the six-minute walk test in dogs","volume":"65","author":"KN Boddy","year":"2004","journal-title":"Am J Vet Res"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0333526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:33:28Z","timestamp":1759167208000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0333526"}},"subtitle":[],"editor":[{"given":"Doa'a G. F.","family":"Al-u'datt","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0333526","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]}}}